Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastasic non-small cell lung cancer: Meta-analysis of randomized and controlled clinical trials;Docetaxel en combinación con cisplatino para el tratamiento en primera línea del cáncer de pulmón no microcítico metastásico o localmente avanzado: Metaanálisis de ensayos clínicos aleatorizados y controlados

Medicina Clinica

Volumn 122, Issue 8, 2004, Pages 281-287

  Sánchez Lerma, Beatriz ^a   Peñuelas Sánchez, Iván ^b   Guillén Grima, Francisco ^c  

^a HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

Author keywords

Cisplatin; Docetaxel; Meta analysis; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; VINDESINE;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; HUMAN; INFECTION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME;

EID: 11144357088     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058675     Document Type: Article

References (35)

1. Organización Mundial de la Salud. Informe Mundial del Cáncer. Génova: OMS, 2003.
2. Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and a examination of emerging therapies. Cancer Control 2001;8:326-36.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
4. Sánchez de la Rosa R, Ruiz Echeverría J, Guillén Grima F. Evaluación del tratamiento con paclitaxel del cáncer de pulmón no microcítico. Med Clin (Barc) 2001;117:167-71.
5. Anon: Press Release: FDA approves Taxotere (docetaxel) for first-line treatment of non-small cell lung cancer. Doctor's Guide Personal Edition, December 3, 2002 [consultado 13/5/2002]. Disponible en: http:/www.docguide.com/news/content.nsf/NewsPrint
6. Pedromingo Marino A, Letón Molina E. Sinergy: Programa estadístico de metanálisis. Versión. 1.1. Manual del programa, documentación y casos prácticos. Tres Cantos: Departamento Biometría. GlaxoSmithKline, 2002.
7. Buchan I. Arcus QuickStat (Biomedical) Versión 1.2. Cambridge: Addison Wesley Longman Ltd., 1998.
8. Belani CP. Docetaxel in combination with (cisplatin or carboplatin) in advanced and metastasic non-small cell lung cancer. Semin Oncol. 2002;29(3 Suppl 12):4-9.
9. Belani CP. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Semin Oncol 2001;28(3 Suppl 9):10-4.
10. Schiller JH, Harrington D, Belani CP, Langer A, Krook J, Zhu J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
11. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Nobuyuki K, et al. Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer. Am Soc Clin Oncol 2002 [consultado 28/02/2002]. Disponible en: http://www.asco.org/asci/meetings_education/2002posters/Abstract1180/poster.htm
12. Kunitoh H, Watanabe K, Ohashi Y, Miitani H. Preliminary results of a randomized phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:1289.
13. Letón Molina E, Pedromingo Marino A. Introducción al análisis de datos en meta-análisis. Madrid: Díaz de Santos, 2001; p. 4.
14. Eager M, Scheider M, Davey-Smith G. Meta-analysis: spurious precision? Meta-analysis of observational studies. BMJ 1998;316:140-4.
15. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Control Clin Trials 1990;11:339-52.
16. Greenland S. Invited commentary: a critical look at some popular metanalytic method. Am J Epidemiol 1994;140:297-9.
17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
18. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials effect estimates of intervention efficacy reported in meta-analysis? Lancet 1998;352:609-13.
19. Peto R. Why do we need systematic overview of randomised trials? Stat Med 1987;6:233-40.
20. Greenland S. Invited commentary: a critical look at some popular meta-analytic method. Am J Epidemiol 1994;140:297-9.
21. Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med 1990;9:247-52.
22. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.
23. nd ed. New York: Wiley, 1981.
24. Alonso Muñoz C, Bonfill X, Dorta Delgado J, Estapé Madinabeitia T, Farré Riba R, Hernández-Bronchud M, et al. El paciente oncohematológico y su tratamiento. Módulos de actualización multidisciplinar. Sociedad Española de Farmacia Hospitalaria (SEFH). Madrid: Editores Médicos 1997;6:50.
25. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastasic breast cancer. Lancet 1989;2:888-91.
26. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping and affective state on recurrence and survival 6 years later. Arch Gen Psychiatr 1993;50:681-9.
27. Gralla JR. Prospective analysis of Quality of Life (QOL) in a randomized multinational Phase III study comparing docetaxel plus either cisplatin or carboplatin with vinorelbine plus cisplatin in patients with advanced non-small cell lung cancer. [resumen 1196] [consultado 22/04/2003]. Disponible en: http://ww3.peerviewpress.com/ peerview.nsf/release/142002 1196.html
28. th Congress of the European Society for Medical Oncology; 2002, Nice, France.
29. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assesment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993;29:S51-S8.
30. nd ed. Philadelphia: Lippincott-Raven Publishers, 1996; p. 191-202.
31. Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23.
32. Georgoulias V, Scagliotti G, Miller V, Eckart J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol 2001;28(1 Suppl 2):15-21.
33. Khuri FR. Docetaxel for locally advanced or metastasic non-small-cell lung cancer. Current data and future directions as front-line treatment. Oncology (Huntingt) 2002;16(6 Suppl 6): 53-62.
34. Green MR. The current status of docetaxel for advanced non-small cell lung cancer. Anticancer Drugs 2001;12(Suppl 1):11-6.
35. Georgoulias V, Androulakis N, Bouros D, Kouroussis C, Chatzakis K, Papadakis M, et al. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 1998;21:213-20.